Review ArticleSystematic Review

Risk of Fracture and Osteoporosis in Patients With COPD and Inhaled Corticosteroids Treatment

Nini Zhang, Xinhui Fan, Yuyu Zhang, Ning Xu and Li Li
Respiratory Care December 2023, 68 (12) 1719-1727; DOI: https://doi.org/10.4187/respcare.10933

REFERENCES

  1. 1.↵
    1. Sandelowsky H,
    2. Weinreich UM,
    3. Aarli BB,
    4. Sundh J,
    5. Høines K,
    6. Stratelis G,
    7. et al
    . COPD - do the right thing. BMC Fam Pract 2021;22(1):244.
    OpenUrl
  2. 2.↵
    1. Man SF,
    2. Sin DD
    . Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005;65(5):579-591.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Singh D,
    2. Agusti A,
    3. Anzueto A,
    4. Barnes PJ,
    5. Bourbeau J,
    6. Celli BR,
    7. et al
    . Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J 2019;53(5):1900164.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Agusti A,
    2. Fabbri LM,
    3. Singh D,
    4. Vestbo J,
    5. Celli B,
    6. Franssen FME,
    7. et al
    . Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018;52(6):1801219.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Casas A,
    2. Montes de Oca M,
    3. Menezes AM,
    4. Wehrmeister FC,
    5. Lopez Varela MV,
    6. Mendoza L,
    7. et al
    . Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis 2018;13:1545-1556.
    OpenUrl
  6. 6.↵
    1. Barrecheguren M,
    2. Monteagudo M,
    3. Ferrer J,
    4. Borrell E,
    5. Llor C,
    6. Esquinas C,
    7. et al
    . Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med 2016;111:47-53.
    OpenUrl
  7. 7.↵
    1. Loke YK,
    2. Cavallazzi R,
    3. Singh S
    . Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomized controlled trials and observational studies. Thorax 2011;66(8):699-708.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Maltais F,
    2. Schenkenberger I,
    3. Wielders P,
    4. Ortiz de Saracho J,
    5. Chinsky K,
    6. Watkins M,
    7. et al
    . Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized controlled trial. Ther Adv Respir Dis 2020;14:1753466620965145.
    OpenUrl
  9. 9.↵
    1. Kerwin EM,
    2. Ferguson GT,
    3. Mo M,
    4. DeAngelis K,
    5. Dorinsky P
    . Bone mineral density and ocular safety after 52 weeks’ treatment with budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler (BGF MDI) using co-suspension delivery technology in COPD. Am J Respir Crit Care Med 2019(9):A3319-A3319.
  10. 10.↵
    1. Rabe KF,
    2. Martinez FJ,
    3. Ferguson GT,
    4. Wang C,
    5. Singh D,
    6. Wedzicha JA,
    7. et al
    ; ETHOS Investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;383(1):35-48.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Lipson DA,
    2. Barnhart F,
    3. Brealey N,
    4. Brooks J,
    5. Criner GJ,
    6. Day NC,
    7. et al
    ; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378(18):1671-1680.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2016;354:i4086.
    OpenUrlFREE Full Text
  13. 13.↵
    1. Cumpston M,
    2. Li T,
    3. Page MJ,
    4. Chandler J,
    5. Welch VA,
    6. Higgins JP,
    7. et al
    . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:Ed000142.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Balshem H,
    2. Helfand M,
    3. Schünemann HJ,
    4. Oxman AD,
    5. Kunz R,
    6. Brozek J,
    7. et al
    . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64(4):401-406.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Anzueto A,
    2. Ferguson GT,
    3. Feldman G,
    4. Chinsky K,
    5. Seibert A,
    6. Emmett A,
    7. et al
    . Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6(5):320-329.
    OpenUrlCrossRefWeb of Science
  16. 16.↵
    1. Bhatt SP,
    2. Dransfield MT,
    3. Cockcroft JR,
    4. Wang-Jairaj J,
    5. Midwinter DA,
    6. Rubin DB,
    7. et al
    . A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. Int J Chron Obstruct Pulmon Dis 2017;12:351-365.
    OpenUrl
  17. 17.↵
    1. Burge PS,
    2. Calverley PM,
    3. Jones PW,
    4. Spencer S,
    5. Anderson JA,
    6. Maslen TK
    . Randomized, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245):1297-1303.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Calverley P,
    2. Pauwels R,
    3. Vestbo J,
    4. Jones P,
    5. Pride N,
    6. Gulsvik A,
    7. et al
    ; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003;361(9356):449-456.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Calverley PM,
    2. Anderson JA,
    3. Celli B,
    4. Ferguson GT,
    5. Jenkins C,
    6. Jones PW,
    7. et al
    ; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-789.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Ferguson GT,
    2. Anzueto A,
    3. Fei R,
    4. Emmett A,
    5. Knobil K,
    6. Kalberg C
    . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102(8):1099-1108.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Ferguson GT,
    2. Tashkin DP,
    3. Skärby T,
    4. Jorup C,
    5. Sandin K,
    6. Greenwood M,
    7. et al
    . Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med 2017;132:31-41.
    OpenUrl
  22. 22.↵
    1. Hanania NA,
    2. Darken P,
    3. Horstman D,
    4. Reisner C,
    5. Lee B,
    6. Davis S,
    7. et al
    . The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124(3):834-843.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Johnell O,
    2. Pauwels R,
    3. Löfdahl CG,
    4. Laitinen LA,
    5. Postma DS,
    6. Pride NB,
    7. et al
    . Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002;19(6):1058-1063.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Kardos P,
    2. Wencker M,
    3. Glaab T,
    4. Vogelmeier C
    . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(2):144-149.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Kerwin EM,
    2. Ferguson GT,
    3. Mo M,
    4. DeAngelis K,
    5. Dorinsky P
    . Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res 2019;20(1):167.
    OpenUrl
  26. 26.↵
    1. Kerwin EM,
    2. Scott-Wilson C,
    3. Sanford L,
    4. Rennard S,
    5. Agusti A,
    6. Barnes N,
    7. Crim C
    . A randomized trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respir Med 2013;107(4):560-569.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Mahler DA,
    2. Wire P,
    3. Horstman D,
    4. Chang C-N,
    5. Yates J,
    6. Fischer T,
    7. Shah T
    . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166(8):1084-1091.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Martinez FJ,
    2. Boscia J,
    3. Feldman G,
    4. Scott-Wilson C,
    5. Kilbride S,
    6. Fabbri L,
    7. et al
    . Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomized trial. Respir Med 2013;107(4):550-559.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Paggiaro PL,
    2. Dahle R,
    3. Bakran I,
    4. Frith L,
    5. Hollingworth K,
    6. Efthimiou J
    . Multi-center randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351(9105):773-780.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Pauwels RA,
    2. Löfdahl CG,
    3. Laitinen LA,
    4. Schouten JP,
    5. Postma DS,
    6. Pride NB,
    7. et al
    . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340(25):1948-1953.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Scanlon PD,
    2. Connett JE,
    3. Wise RA,
    4. Tashkin DP,
    5. Madhok T,
    6. Skeans M,
    7. et al
    ; Lung Health Study Research Group. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004;170(12):1302-1309.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Siler TM,
    2. Nagai A,
    3. Scott-Wilson CA,
    4. Midwinter DA,
    5. Crim CA
    . Randomized, phase 3 trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med 2017;123:8-17.
    OpenUrl
  33. 33.↵
    1. Tashkin DP,
    2. Doherty DE,
    3. Kerwin E,
    4. Matiz-Bueno CE,
    5. Knorr B,
    6. Shekar T,
    7. et al
    . Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week phase 3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:43-55.
    OpenUrlPubMed
  34. 34.↵
    1. Vestbo J,
    2. Anderson JA,
    3. Brook RD,
    4. Calverley PM,
    5. Celli BR,
    6. Crim C,
    7. et al
    ; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomized controlled trial. Lancet 2016;387(10030):1817-1826.
    OpenUrlPubMed
  35. 35.↵
    1. Vestbo J,
    2. Leather D,
    3. Bakerly ND,
    4. New J,
    5. Martin Gibson J,
    6. McCorkindale S,
    7. et al
    ; Salford Lung Study Investigators. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med 2016;375(13):1253-1260.
    OpenUrlPubMed
  36. 36.↵
    1. Wang C,
    2. Yang T,
    3. Kang J,
    4. Chen R,
    5. Zhao L,
    6. He H,
    7. et al
    . Efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler in Chinese patients with COPD: a subgroup analysis of KRONOS. Adv Ther 2020;37(4):1591-1607.
    OpenUrl
  37. 37.↵
    1. Wouters EF,
    2. Postma DS,
    3. Fokkens B,
    4. Hop WC,
    5. Prins J
    . Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial. Revista Portuguesa de Pneumologia 2005;11(6):587-589.
    OpenUrlPubMed
  38. 38.↵
    1. Etminan M,
    2. Sadatsafavi M,
    3. Ganjizadeh Zavareh S,
    4. Takkouche B,
    5. FitzGerald JM
    . Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf 2008;31(5):409-414.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Drummond MB,
    2. Dasenbrook EC,
    3. Pitz MW,
    4. Murphy DJ,
    5. Fan E
    . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-2416.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Derendorf H
    . Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997;91 Suppl A:22-28.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Weatherall M,
    2. James K,
    3. Clay J,
    4. Perrin K,
    5. Masoli M,
    6. Wijesinghe M,
    7. et al
    . Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy 2008;38(9):1451-1458.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Ferguson GT,
    2. Calverley PMA,
    3. Anderson JA,
    4. Jenkins CR,
    5. Jones PW,
    6. Willits LR,
    7. et al
    . Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009;136(6):1456-1465.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Chiu KL,
    2. Lee CC,
    3. Chen CY
    . Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. Sci Rep 2021;11(1):724.
    OpenUrl
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords